Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BLRX |
---|---|---|
09:32 ET | 1728 | 0.5629 |
09:34 ET | 4720 | 0.5625 |
09:36 ET | 263 | 0.57 |
09:38 ET | 700 | 0.57 |
09:39 ET | 600 | 0.57 |
09:41 ET | 680 | 0.5728 |
09:43 ET | 3400 | 0.5611 |
09:48 ET | 2800 | 0.5611 |
10:01 ET | 179 | 0.5796 |
10:03 ET | 500 | 0.5797 |
10:12 ET | 17200 | 0.565 |
10:14 ET | 35200 | 0.565 |
10:15 ET | 8900 | 0.565 |
10:19 ET | 1809 | 0.5611 |
10:30 ET | 2500 | 0.5607 |
10:33 ET | 280 | 0.5749 |
10:44 ET | 1000 | 0.561101 |
10:46 ET | 11000 | 0.5611 |
10:53 ET | 900 | 0.5611 |
10:57 ET | 200 | 0.5602 |
11:09 ET | 528 | 0.5608 |
11:18 ET | 587 | 0.57 |
11:20 ET | 900 | 0.568 |
11:22 ET | 251 | 0.5679 |
11:24 ET | 1500 | 0.5659 |
11:26 ET | 100 | 0.5649 |
11:29 ET | 33464 | 0.5612 |
11:33 ET | 1640 | 0.5613 |
11:58 ET | 33935 | 0.5612 |
12:05 ET | 12000 | 0.5612 |
12:21 ET | 42116 | 0.56 |
12:32 ET | 600 | 0.567 |
12:34 ET | 4100 | 0.567699 |
12:43 ET | 200 | 0.5676 |
12:45 ET | 400 | 0.5675 |
12:48 ET | 4600 | 0.5602 |
12:52 ET | 100 | 0.5653 |
12:54 ET | 100 | 0.5675 |
12:57 ET | 231 | 0.5674 |
12:59 ET | 900 | 0.5674 |
01:01 ET | 200 | 0.5674 |
01:06 ET | 2500 | 0.5637 |
01:08 ET | 100 | 0.56694 |
01:15 ET | 200 | 0.5673 |
01:26 ET | 26400 | 0.5674 |
01:28 ET | 600 | 0.575 |
01:42 ET | 100 | 0.57 |
01:44 ET | 338 | 0.5713 |
01:48 ET | 220 | 0.5749 |
01:51 ET | 540 | 0.571 |
02:00 ET | 100 | 0.571 |
02:08 ET | 600 | 0.5711 |
02:09 ET | 5700 | 0.565951 |
02:24 ET | 100 | 0.5748 |
03:02 ET | 1800 | 0.5675 |
03:56 ET | 1428 | 0.5699 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
BioLine RX Ltd | 48.9M | -0.7x | --- |
Marker Therapeutics Inc | 48.4M | -3.9x | --- |
LAVA Therapeutics NV | 47.3M | -1.7x | --- |
Cue Biopharma Inc | 60.3M | -1.2x | --- |
Lipocine Inc | 44.1M | -4.8x | --- |
Palatin Technologies Inc | 31.5M | -0.8x | --- |
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.9M |
---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 4.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.